...We Welcome You To The Resverlogix HUB In The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Message: Abstract - first example of a "curative" effect?


Thanks for the comment. Looks like this is your first post on Agoracom, but you've been a member for a bit. So a belated welcome to Agoracom. A courteous request.....please actually post a link when you reference something like an article on PubMed. There's already a poster on a differnt Resverlogix hub who frequently sends others on PubMed scavenger hunts with cryptic posts. Please don't do that here.

All you need to do is copy and past the url like this:


Or you can get fancy and use that little chain link icon button in the toolbar to hyperlink the url to the text of your choosing like this:

NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells

Best Regards,


New Message
Please login to post a reply